Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021
Table of Contents
1 Introduction
1.1 Objectives of the Study
1.2 Cancer Immunotherapy Market Definition
1.3 Markets Covered
1.3.1 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
2 Research Methodology
2.1 Cancer Immunotherapy Market Size Estimation
2.2 Cancer Immunotherapy Market Breakdown and Data Triangulation
2.3 Cancer Immunotherapy Market Share Estimation
2.3.1 Key Data From Secondary Sources
2.3.2 Key Data From Primary Sources
2.4 Assumptions for the Study
3 Executive Summary
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
4 Premium Insights
4.1 Lucrative Opportunities in the Cancer Immunotherapy Market
5 Market Overview
5.1 Introduction
5.1.1 Drivers
5.1.1.1 Rise in Incidence Rate of Cancer Worldwide
5.1.1.2 Increase in Adoption of Immunotherapy Over Other Treatment Options
5.1.1.3 Development of Bioinformatics Tools are Enhancing Drug Development Process
5.1.2 Restraints
5.1.2.1 High Cost of Treatment
5.1.3 Opportunities
5.1.3.1 Increase in Clinical Trials Against Several Types of Cancers in Immunotherapy
5.1.3.2 High Growth Projections in the Developing Countries
5.1.4 Challenges
5.1.4.1 Availability of Limited Funds to Initiate Clinical Trials
5.1.4.2 Complexity of Cancer May Limit the Immune Response
5.2 Overview of Global Cancer Immunotherapy Funding
6 Industry Trends
6.1 Global Trends in Cancer Immunotherapy Market
6.1.1 Opdivo (Niolumab) and Keytruda (Pembrolizumab) Fda Approval in U.S. Increases Hope Amongst Lung Cancer Patients
6.1.2 Combination Immunotherapy Potential Way to Treat Melanoma
6.1.3 U.S. Cancer Immunotherapy Research Community Builds Hope to Combat Cancer By 2020
6.1.4 U.K. Scientists Project A Change in the Means of Treatment for Cancer With Quality Therapies
6.1.5 World is Moving Toward Personalized Immunotherapy
6.1.6 A Combination of Modern Immunotherapy and Traditional Chinese Medicines Continues to Increase Survival Rate of Patients in China
6.2 Pricing Variations in Global Cancer Immunotherapy Market
6.3 Small Players Getting Together to Make Long Term Impact in Cancer Immunotherapy Market
6.4 Attractions for Pharmaceutical Industry
6.5 Heat Map for Variations in Cancer Immunotherapy for Different Types of Cancers
6.5.1 Breast Cancer
6.5.2 Lung Cancer
6.5.3 Multiple Myeloma
6.5.4 Lymphoma
7 Cancer Immunotherapy Market, By Product Type
7.1 Introduction
7.2 Monoclonal Antibodies
7.2.1 Naked Monoclonal Antibodies
7.2.2 Conjugated Monoclonal Antibodies
7.2.3 Bispecific Monoclonal Antibodies
7.3 Vaccines
7.3.1 Prophylactic Vaccines
7.3.2 Therapeutic Vaccines
7.4 Check Point Inhibitors
7.4.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
7.4.2 Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
7.5 Cell Therapies
7.5.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
7.5.2 Dendritic Cells
7.6 Immunomodulators
7.6.1 Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF)
7.6.2 Interferons (IFN)
7.6.3 Interleukins (IL)
7.6.4 Oncolytic Virus
7.6.4.1 Immunotherapy
7.6.4.1 Immunity as an Obstacle
7.6.4.2 Immunity as an Ally
7.6.4.3 Approved Products & Clinical Trails
8 Cancer Immunotherapy Market, By Application
8.1 Introduction
8.2 Lung Cancer
8.3 Breast Cancer
8.4 Multiple Myeloma
8.5 Colorectal Cancer
8.6 Head & Neck Cancer
8.7 Prostate Cancer
8.8 Melanoma
8.9 Other Cancer Types
9 Cancer Immunotherapy Market, By End User
9.1 Introduction
9.2 Hospital
9.3 Clinics and Others
10 Cancer Immunotherapy Market, By Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Rest of the World (RoW)
11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Situation and Trends
11.3.1 Approvals
11.3.2 Agreements, Partnerships, and Collaborations
11.3.3 Acquisitions
11.3.4 Expansions
11.3.5 Other Developments
12 Company Profile
(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*
12.1 Amgen Inc.
12.2 Astrazeneca
12.3 Bayer AG
12.4 Bristol-Myers Squibb
12.5 Eli Lilly and Company
12.6 Janssen Global Services, LLC (Johnson and Johnson)
12.7 Merck
12.8 Novartis
12.9 Pfizer
12.10 F. Hoffmann-LA Roche Ltd
*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix
13.1 Insights From Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT : Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
List of Tables
Table 1 Overview of Funding Pattern in Different Types of Cancer By Nih, U.S., 2012–2017 (USD Million)
Table 2 Overview of Key Funding in Cancer Immunotherapy Market, 2016
Table 3 Conventional Cancer Therapy Versus Cancer Immunotherapy
Table 4 Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 5 Cancer Monoclonal Antibodies Market Size, By Subtype, 2014–2021 (USD Million)
Table 6 Cancer Monoclonal Antibodies Market, By Region, 2014–2021 (USD Million)
Table 7 Naked Monoclonal Antibodies Market, By Region, 2014–2021 (USD Million)
Table 8 Conjugated Monoclonal Antibodies Market, By Region, 2014–2021 (USD Million)
Table 9 Bispecific Monoclonal Antibodies Market Size, By Region, 2014–2021 (USD Million)
Table 10 Vaccines Market, By Subtype, 2014–2021 (USD Million)
Table 11 Vaccines Market, By Region, 2014–2021 (USD Million)
Table 12 Prophylactic Vaccines Market Size, 2014–2021 (USD Million)
Table 13 Therapeutic Vaccines Market, By Region, 2014–2021 (USD Million)
Table 14 Checkpoint Inhibitors Market Size, By Subtype, 2014–2021 (USD Million)
Table 15 Checkpoint Inhibitors Market, By Region, 2014–2021 (USD Million)
Table 16 Cytoxic T-Lymphocyte Market Size, By Region, 2014–2021 (USD Million)
Table 17 Cytoxic T-Lymphocyte Market Size, By Region, 2014–2021 (USD Million)
Table 18 Immunomodulators Market Size, By Subtype, 2014–2021 (USD Million)
Table 19 Immunomodulators Market Size, By Region, 2014–2021 (USD Million)
Table 20 Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) Market Size, By Region, 2014–2021 (USD Million)
Table 21 Interferons Market Size, By Region, 2014–2021 (USD Million)
Table 22 Interleukins Market Size, By Region, 2014–2021 (USD Million)
Table 23 Cancer Immunotherapy Market Size, By Application, 2014–2021 (USD Million)
Table 24 Lung Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 25 Breast Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 26 Multiple Myeloma Market Size, By Region, 2014–2021 (USD Million)
Table 27 Colorectal Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 28 Head & Neck Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 29 Prostate Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 30 Melanoma Market Size, By Region, 2014–2021 (USD Million)
Table 31 Other Types of Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 32 Cancer Immunotherapy Market Size, By End User, 2014–2021 (USD Million)
Table 33 Hospitals Market Size, By Region, 2014–2021 (USD Million)
Table 34 Clinics and Others Market Size, By Region, 2014–2021 (USD Million)
Table 35 Cancer Immunotherapy Market Size, By Region, 2014–2021 (USD Million)
Table 36 North America: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 37 Europe: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 38 Asia-Pacific: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 39 RoW: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 40 Approvals, 2013–2016
Table 41 Agreements, Partnerships, and Collaborations, 2013–2016
Table 42 Acquisitions, 2013–2016
Table 43 Expansions, 2013–2016
List of Figures
Figure 1 Classification of Cancer Immunotherapy
Figure 2 Research Design
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 The Monoclonal Antibody Segment is Expected to Lead the Global Cancer Immunotherapy Market During the Forecast Period
Figure 8 The Lung Cancer Segment to Lead the Global Cancer Immunotherapy Market in 2016
Figure 9 Hospitals are Major End Users of the Global Cancer Immunotherapy Market
Figure 10 North America Led the Global Cancer Immunotherapy Market in 2015
Figure 11 Future of Cancer Immunotherapeutics
Figure 12 Global Cancer Immunotherapy Market to Witness High Growth During the Forecast Period
Figure 13 Lung Cancer Application Dominated the Global Cancer Immunotherapy Market, 2016
Figure 14 Asia-Pacific to Witness the Fastest Growth During the Forecast Period
Figure 15 Lung Cancer to Witness the Fastest Growth During the Forecast Period in the Cancer Immunotherapy Market
Figure 16 Drivers, Restraints, Opportunities, and Challenges
Figure 17 Population Forecasts for All Cancers Excluding Non-Melanoma Skin Cancer, 2012 vs 2020
Figure 18 Pricing Trend of Imbruvica Across Major Pharmaceutical Market in 2016
Figure 19 Heat Map Showing Variations in Immunotherapy Drugs Used for Breast Cancer
Figure 20 Annual Cost of Breast Cancer Immunotherapy, 2016
Figure 21 Heat Map Showing Variations in Immunotherapy Drugs Used for Lung Cancer
Figure 22 Annual Cost of Lung Cancer Immunotherapy, 2016
Figure 23 Heat Map Showing Variations in Immunotherapy Drugs Used for Multiple Myeloma
Figure 24 Annual Cost of Multiple Myeloma Immunotherapy, 2016
Figure 25 Heat Map Showing Variations in Immunotherapy Drugs Used for Lymphoma
Figure 26 Annual Cost of Lymphoma Immunotherapy, 2016
Figure 27 Cancer Immunotherapy Market Size, By Product Type
Figure 28 Monoclonal Antibodies Segment to Dominate the Cancer Immunotherapy Market Size in 2016
Figure 29 Naked Monoclonal Antibodies to Account for the Largest Share in 2016
Figure 30 North America to Account for the Largest Share of the Cancer Monoclonal Antibodies Market in 2016
Figure 31 Vaccines Market Size, By Subtype, 2016–2021 (USD Million)
Figure 32 Asia-Pacific Expected to Be the Fastest-Growing Regional Segment of the Vaccines Market
Figure 33 Programmed Death 1(PD-1) is Expected to Be the Fastest-Growing Segment of the Check Point Inhibitors Market
Figure 34 RoW is Expected to Account the Fastest-Growing Regional Segment of the Checkpoint Inhibitors Market
Figure 35 GM-CSF & G-CSF Segment is Expected to Dominate the Immunomodulators Market in 2016
Figure 36 North America is Expected to Account for the Largest Share in the Immunomodulators Market Through 2021
Figure 37 Cancer Immunotherapy Market, By Application
Figure 38 Lung Cancer Segment Leads the Cancer Immunotherapy Market Size in 2016
Figure 39 North America Accounts for the Largest Share of the Lung Cancer Immunotherapy Market in 2016
Figure 40 North America Accounts for the Largest Share of the Cancer Immunotherapy Market for Breast Cancer in 2016
Figure 41 North America Accounts for the Largest Share of the Cancer Immunotherapy Market for Multiple Myeloma in 2016
Figure 42 North America Accounts for the Largest Share of the Cancer Immunotherapy Market for Colorectal Cancer in 2016
Figure 43 North America Estimated to Account for the Largest Share of the Immunotherapy Market for Head & Neck Cancer in 2016
Figure 44 North America Estimated to Dominate the Immunotherapy Market for Prostate Cancer in 2016
Figure 45 North America is Projected to Be the Fastest-Growing Region in the Cancer Immunotherapy Market for Melanoma During the Forecast Period
Figure 46 Asia-Pacific is Projected to Be the Fastest-Growing Region in the Immunotherapy Market for Other Cancer Types, 2016-2021
Figure 47 Cancer Immunotherapy Market, By End User, 2016 vs 2021 (USD Million)
Figure 48 Hospitals Market Size, 2016 vs 2021, By Region (USD Million)
Figure 49 Clinics and Others Market Size, By Region, 2016 vs 2021 (USD Million)
Figure 50 Geographic Snapshot: Asia-Pacific is Projected to Be the Fastest-Growing Region During the Forecast Period
Figure 51 Checkpoint Inhibitors Segment is Projected to Grow at the Highest Rate From 2016 to 2021
Figure 52 North America: Cancer Immunotherapy Market Snapshot, 2016
Figure 53 The Check Point Inhibitors is Projected to Be the Fastest-Growing Market in North America During the Forecast Period
Figure 54 Monoclonal Antibodies Segment is Projected to Dominate the Cancer Immunotherapy Market in Europe Till 2021
Figure 55 Asia-Pacific: Cancer Immunotherapy Market Snapshot, 2016
Figure 56 Checkpoint Inhibitors Segment is Expected to Lead the Cancer Immunotherapy Market in the RoW Region Till 2021
Figure 57 Companies Adopted Approvals as Their Key Growth Strategy Over the Last Three Years
Figure 58 Global Cancer Immunotherapy Market Share, By Key Player, 2015
Figure 59 Approvals: the Key Growth Strategy Adopted By Market Players From 2013 to 2015
Figure 60 Amgen: Company Snapshot
Figure 61 Astrazeneca: Company Snapshot
Figure 62 Bayer AG: Company Snapshot
Figure 63 Bristol-Myers Squibb: Company Snapshot
Figure 64 Eli Lilly and Company: Company Snapshot
Figure 65 Janssen Global Services, LLC: Company Snapshot
Figure 66 Merck: Company Snapshot
Figure 67 Novartis; Company Snapshot
Figure 68 Pfizer : Company Snapshot
Figure 69 F. Hoffmann-LA Roche Ltd.: Company Snapshot
Global Cancer Immunomodulator Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 95
The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 158
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 131
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 125
According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period.
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
Published: 27-Dec-2023 Price: US 3350 Onwards Pages: 112
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Dec-2023 Price: US 3380 Onwards Pages: 101
Market Overview of Global Cancer Gene Therapy market:
According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
Published: 25-Dec-2023 Price: US 3350 Onwards Pages: 85
CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively.
The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
Global Kaposi Sarcoma Market Status and Outlook 2023-2028
Published: 22-Dec-2023 Price: US 3160 Onwards Pages: 107
Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 21-Dec-2023 Price: US 3380 Onwards Pages: 118
Market Overview of Global Cancer Immunomodulator market:
According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs